XOMA (NASDAQ:XOMA) Earns Buy Rating from HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $123.00 price objective on the biotechnology company’s stock, up from their previous price objective of $117.00. HC Wainwright’s target price would indicate a potential upside of 288.50% from the company’s current price.

Separately, StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th.

XOMA Price Performance

Shares of NASDAQ:XOMA opened at $31.66 on Monday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 1 year low of $14.77 and a 1 year high of $35.00. The business has a fifty day simple moving average of $29.57 and a 200 day simple moving average of $27.46. The firm has a market cap of $372.95 million, a price-to-earnings ratio of -9.10 and a beta of 0.88.

Insider Activity at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now directly owns 34,979 shares in the company, valued at $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA

A number of institutional investors have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets boosted its holdings in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in XOMA during the first quarter valued at approximately $212,000. Rhumbline Advisers boosted its holdings in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Barclays PLC boosted its holdings in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Finally, Ellsworth Advisors LLC acquired a new stake in XOMA during the third quarter valued at approximately $516,000. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.